Lieping Chen
Lieping Chen
United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Medicine (Medical Oncology) and Dermatology
Yale School of Medicine
Elected to the Academy in 2022


Fujian Medical University (Fuzhou, China), 1982, MD; Beijing Union Medical College (Beijing, China), 1986, MSc, Microbiology & Immunology; Drexel University College of Medicine, 1989, PhD, Pathology

Professional Area

Immunologist and research oncologist with interests in understanding how to control and modulate immune responses to fight cancer as well as autoimmune and inflammatory diseases.


Pioneer in the field of cancer immunotherapy, including fundamental research that led to the cloning of B7-H1(PD-L1), subsequent demonstration of the immunosuppressive functions of the B7-H1/PD-1 signaling pathway; use of antibody blockade of this pathway as a cancer immunotherapy; pivotal discovery of costimulation as a mechanism to improve tumor immunity, leading to the development of breakthrough treatments for human cancer.